Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC2 | Q92769 | 2/20 | 0.42 |
| ▸ | DRD2 | P14416 | 2/20 | 0.39 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | DRD1 | P21728 | 1/20 | 0.36 |
| ▸ | DRD4 | P21917 | 1/20 | 0.36 |
| ▸ | DRD5 | P21918 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22296049 | 0.86 | HDAC2 (0.40) | HDAC2DRD2SLC18A3SIGMAR1DRD1 | |
| SCHEMBL19995891 | 0.81 | HDAC2 (0.49) | HDAC2SLC18A3SIGMAR1 | |
| SCHEMBL4378036 | 0.81 | HTR2C (0.44) | HDAC2SLC18A3SIGMAR1 | |
| SCHEMBL350327 | 0.81 | HDAC2 (0.49) | HDAC2SLC18A3SIGMAR1 | |
| Hydrochloric Acid SCHEMBL18631883 | 0.80 | HDAC2 (0.48) | HDAC2SLC18A3SIGMAR1 | |
| SCHEMBL8512642 | 0.77 | HDAC2 (0.49) | HDAC2 | |
| SCHEMBL8514600 | 0.77 | HDAC2 (0.49) | HDAC2 | |
| SCHEMBL9965342 | 0.77 | HTR2C (0.38) | DRD3 | |
| Hydrochloric Acid SCHEMBL9543359 | 0.76 | HDAC2 (0.48) | HDAC2 | |
| SCHEMBL4207545 | 0.75 | HDAC2 (0.45) | HDAC2SLC18A3SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230012449-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. | 2023-01-12 | — | — | US | disclosed |
| US-11034668-B2 | Compounds for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2021-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11034668-B2 | Compounds for the treatment of HIV | CCR5, NPC1, FURIN | HDAC2 1213/4885DRD2 4227/4885SLC18A3 1196/4885 |
| US-20230012449-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | CCR5, NPC1, FURIN | HDAC2 1213/4885DRD2 4227/4885SLC18A3 1196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.